Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

NCT02330406 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

353

Enrollment

OTHER

Sponsor class

Conditions

Dipeptidyl-Peptidase 4 Inhibitors
LDL Cholesterol
Glycosylated Hemoglobin
Diabetes Mellitus
Coronary Disease

Interventions

DRUG: Anagliptin
DRUG: Sitagliptin

Sponsor

Institute for Clinical Effectiveness, Japan